Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 AUD | 0.00% | 0.00% | -9.09% |
04-22 | Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data | MT |
04-22 | PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.09% | 339M | - | ||
+22.56% | 46.4B | B- | ||
-1.51% | 41.75B | B | ||
+48.83% | 41.37B | A | ||
-3.42% | 29.71B | C | ||
+10.13% | 26.01B | B- | ||
-20.44% | 19.52B | B | ||
+26.45% | 12.43B | C+ | ||
-0.14% | 12.18B | B+ | ||
-0.47% | 12.13B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PYC Stock
- Ratings PYC Therapeutics Limited